Relay Therapeutics Inc. (NASDAQ:RLAY) previous close was $32.99 while the outstanding shares total 90.20M. RLAY’s shares traded lower over the last trading session, losing -2.82% on 06/03/21. The shares fell to a low of $31.99 before closing at $32.06. Intraday shares traded counted 0.6 million, which was 11.43% higher than its 30-day average trading volume of 682.04K. The stock’s Relative Strength Index (RSI) is 52.08, with weekly volatility at 4.24% and ATR at 1.66. The RLAY stock’s 52-week price range has touched low of $26.44 and a $64.37 high.
Investors have identified the Biotechnology company Relay Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $3.00 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Relay Therapeutics Inc. (RLAY) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 742.43 million total, with 16.08 million as their total liabilities.
RLAY were able to record 46.16 million as free cash flow during the 09/02/2021 quarter of the year, this saw their quarterly net cash flow reduce by -184.93 million. In cash movements, the company had a total of 46.64 million as operating cash flow.
Potential earnings growth for Relay Therapeutics Inc. (RLAY)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.95 million trying to sell their products during the last quarter, with the result yielding a gross income of 43.36 million. This allows shareholders to hold on to 90.20M with the recently reported earning now reading -0.47 cents per share. This is a figure that compared to analyst’s prediction for their 09/02/2021 (-0.47 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.90 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on RLAY sounds very interesting.
Is the stock of RLAY attractive?
In related news, General Counsel, Adams Brian sold 6,500 shares of the company’s stock in a transaction that recorded on Apr 26. The sale was performed at an average price of 35.00, for a total value of 227,500. As the sale deal closes, the See Remarks, Bergstrom Donald A now sold 56,324 shares of the company’s stock, valued at 1,822,645. Also, General Counsel, Adams Brian sold 5,000 shares of the company’s stock in a deal that was recorded on Jan 28. The shares were price at an average price of 55.05 per share, with a total market value of 275,250. Following this completion of acquisition, the 10% Owner, Third Rock Ventures III, L.P. now holds 1,965,294 shares of the company’s stock, valued at 80,577,054. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.60%.
5 out of 6 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Relay Therapeutics Inc.. 0 analysts has assigned a Sell rating on the RLAY stock. The 12-month mean consensus price target for the company’s shares has been set at $54.40.